Galderma Group AG (GALD) Stock Analysis & DCF Valuation
GALD · SIX Swiss Exchange ·
Medium confidence
Galderma is a global leader in medical dermatology, commanding a strong position in injectable aesthetics and therapeutic skincare.
Galderma Group AG Intrinsic Value & DCF Valuation
Our discounted cash flow (DCF) model estimates Galderma Group AG fair value at $NaN per share, compared to the current market price of $NaN. This implies +35.3% upside from today's price.
| Fair Value (DCF) | $NaN |
| Current Market Price | $NaN |
| Upside / Downside | +35.3% |
GALD Key Financial Metrics
| Market Cap | $19.85B |
| P/E Ratio | 32.4 |
| Dividend Yield | 0.65% |
| Analyst Target Price | $98.50 |
Galderma Group AG Long-Term Stock Outlook
Galderma remains well-positioned to benefit from the secular growth of the global medical aesthetics market through its innovation-led approach.
Bullish Factors
- [object Object]
- [object Object]
- [object Object]
Key Risks
- [object Object]
- [object Object]
- [object Object]
GALD Analyst Sentiment & Market Consensus
Market analysts maintain a broadly positive outlook, citing strong top-line growth and effective geographical expansion strategies in Asia and North America.
Should You Buy GALD Stock?
Recommendation: Buy Medium confidence
No recommendation provided
Frequently Asked Questions
Is GALD a good stock to buy?
Based on our AI analysis, Galderma Group AG (GALD) is rated as Buy with medium confidence. Galderma is a global leader in medical dermatology, commanding a strong position in injectable aesthetics and therapeutic skincare.
What is GALD stock price target?
Our DCF valuation model estimates Galderma Group AG (GALD) fair value at $NaN, suggesting +35.3% downside potential from current price of $NaN.
What is GALD fair value?
The fair value for Galderma Group AG (GALD) is estimated at $NaN based on discounted cash flow (DCF) analysis. This represents +35.3% downside from the current price.
*This analysis is for informational purposes only and should not be taken as financial advice.*
© 2025 stockpickr - AI-Powered Stock Analysis